The association of genetic polymorphisms of BAG-1 and ERCC 1 with the clinical response to platinum drugs in patients with advanced non-small cell lung cancer

Objective: To investigate the association of genetic polymorphisms of Bcl-2 associated athanogene 1 (BAG -1) codon 324 (C→T, rs11551682) and excision repair cross-complementing group 1 (ERCC 1) codon 118 (C→T, rsl1615) with the response to platinum drugs in patients with advanced non-small cell lung cancer (NSCLC). Methods: The genotypes of BAG -1 codon 324 and ERCC 1codon 118 were determined by PCR-restriction fragment length polymorphism (PCR-RFLP) method in 142 patients with advanced NSCLC receiving platinum-based chemotherapy. The association of different genotypes with the clinical response to platinum drugs was analyzed. Results: The allele frequencies of C/C, C/T and T/T of BAG -1 codon 324 were 77.46% (110/142), 22.54% (32/142) and 0% (0/142), respectively. Of 142 patients, 4 achieved complete response, 42 achieved partial response, 55 achieved stable response, and 41 achieved progressive disease; the overall response rate was 32.39%. The response rate of BAG -1 codon 324 C/C allele carriers was 2.852-fold higher than that of C/T allele carriers (95% confidence interval: 1.133-7.182; P ＝0.026), and there was a significant difference in progression-free survival between patients carrying with BAG -1 codon 324 C/C and C/T (5.7 months vs 5.3 months, P ＝0.002). The two genetic polymorphisms — BAG -1 codon 324 C/C and ERCC 1 codon 118 C/C had some synergistic effects on the response to platinum drugs (P ＝0.005). Conclusion: The genotypes of BAG -1 codon 324 and ERCC 1 codon 118 may be predictive factors for response to platinum drugs in the treatment of advanced NSCLC. DOI: 10.3781/j.issn.1000-7431.2011.09.009